Skip to main content

Millar Kerri-Ann's Form 4 filing

Cue Biopharma, Inc.CUE · filed Oct 5, 2021

Accession no.
0001209191-21-059698
Filed
Oct 5, 2021
Trade date
Aug 23-Oct 1, 2021
Filing delay
43 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $17.8K. It was filed 43 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Millar Kerri-AnnCIK 0001739126Officer (CHIEF FINANCIAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 23, 2021Common StockMOption exerciseAcquired+6,667$0.00$012,433Direct
Aug 23, 2021Common StockFTax withholdingDisposed−1,961$0.00$010,472Direct
Oct 1, 2021Common StockMOption exerciseAcquired+1,251$7.50+$9,382.511,723Direct
Oct 1, 2021Common StockSSaleDisposed−1,251$14.21F3−$17,776.7110,472Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 23, 2021Common StockMOption exerciseDisposed−6,667$0.00$06,667Direct
Oct 1, 2021Common StockMOption exerciseDisposed−1,251$0.00$053,749Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.01 to $14.46, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)